1. DRUG RECEPTORS AND PHARMACODYNAMICS

2. PAUL EHRLICH
Drugs cannot act unless they are bound to receptors

3. PROTEIN TARGETS FOR DRUG BINDING
4 main kinds of regulatory protein are commonly involved as primary drug targets
Receptors
Enzymes methotrexate-dihydrofolate reductase
Carrier molecules (transporters) (SSRI, TCA)
Ion channels local anesthetics-voltage sensitive Na channel

4. Pharmacodynamics Is what the drug does to the body.
Interaction of drugs with cellular proteins, such as receptors or enzymes, to control changes in physiological function of particular organs.
Drug-Receptor Interactions
Binding
Dose-Response
Effect
Signal Transduction
Mechanism of action, Pathways

5. PHARMACODYNAMICS 2
Receptors largely determine the quantitative relations between dose or concentration of drug and pharmacologic effects
Receptors are responsible for selectivity of drug action, the molecular size, shape and electrical charge of a drug determine its binding characteristics
Receptors mediate the actions of both pharmacologic agonists and antagonists

6. Drug receptor
A protein macromolecule produced by the body that was designed by nature to interact with an endogenous molecule (ligand), but which will also interact with a drug molecule, if it has the correct chemical structure

7. Levels of protein structure
Primary→ sequence of aa that make up the pp chain
Secondary →interaction of + charged H atoms with – charges O atoms on C from the same polypeptide chain
Tertiary → interaction of aa that are relatively far apart on the protein backbone
Quaternary → binding interaction among 2 or more independent protein subunits

8. Some receptor characteristics…
Ability to recognize specific molecular shapes:
only a limited group of neurochemicals or drugs can bind to initiate a cellular response

9. Endogenous compounds act on their receptors
Neurotransmitter
Neuropeptides
Hormones
Ions

10. Best fit -- highest affinity
Some fit; no cellular effect; block receptor preventing its activation by drug or neurochemical or hormone
The ability of a drug to activate a receptor and generate a cellular response is its efficacy

11. Some receptor characteristics…
 Binding of ligand is only temporary
 Ligand binding produces physical changes in protein conformation, initiating intracellular changes that ultimately generates behavioral effects.
 Receptors have a life cycle (as other proteins do). Receptors can be modified in numbers (long-term regulation) and in sensitivity.
Receptors can up-regulate: increase in numbers (chronic absence of agonist)
Down-regulate: decrease in numbers (chronic presence of agonist)

12. PHARMACODYNAMICS AGONISTS & ANTAGONISTS
Receptors mediate the actions of both pharmacologic agonists and antagonists.
Some drugs and many natural ligands such as hormones and neurotransmitters activate the receptor to signal as a direct result of binding to it. Agonists (Full agonists, Partial agonists, Inverse agonists)
Antagonists bind to receptors but do not activate generation of a signal, they interfere with the ability of an agonist to activate the receptor.

13. Agonist

14. There are 3 types of agonist...
Full agonist: Produces the maximal responce
Partial agonist (agonist-antagonist or mixed agonist-antagonist): produces the submaximal responce
*In the presence of full agonist, a partial agonist will act like an antagonist because it prevents the full agonist to bind the receptor

15. An antagonist occupies but does not activate the drug receptor

16. KD=k-1/k+1

17. Types of drug antagonism
chemical antagonism (interaction in solution)
pharmacokinetic antagonism (one drug affecting the absorption, metabolism or excretion of the other)
competitive antagonism (both drugs binding to the same receptors); the antagonism may be reversible or irreversible
interruption of receptor-effector linkage
physiological antagonism (two agents producing opposing physiological effects)

20. THE 2 STATE MODEL

21. BINDING WITH RECEPTORS BONDS
Ionic bonds
Hydrogen bonds
Dispersion forces (Van der Waals)
Covalent bonds

22. BONDS 2

23. BONDS 3

26. Reversible antagonists briefly occupy their receptors

27. Inhibition caused by reversible antagonist overcome by adequate concentration of agonist at receptor site
Reversible antagonist
Agonist
RESPONSE

28. COMPETITIVE INHIBITION

29. Irreversible antagonists permanently occupy (bond covalently) to their receptors

31. NONCOMPETITIVE INHIBITION

32. COVALENT BONDS

33. Dose-response relationships
The relationship between the concentration of drug at the receptor site and the magnitude of the response is called the dose-response relationship
Depending on the purpose of the the studies, this relatioship can be described in terms of a graded (continous) response or a quantal (all-or-none) response

34. graded dose-response relationship
In this relationship; percentage of a maximal response is plotted against the log dose of the drug
Illustrates the relatioship between drug dose, receptor occupancy and the magnitude of the resulting physiologic effect
It follows from receptor theory that the maximal response to a drug occurs when all receptors that can be occupied by that drug

35. RELATION BETWEEN DRUG CONCENTRATION AND RESPONSE

37. Dose-response (dose-effect) curve
Half maximal response indicates that 50% of the reseptors are occupied
Maximal response indicates that, all receptors are occupied by drug
EC 50
Median effective dose

38. drug efficacy The ability of a drug to elicit a maximal response
Also called intrinsic activity of a drug
Therapeutic efficacy, or effectiveness, is the capacity of a drug to produce an effect and refers to the maximum such effect. For example, if drug A can produce a therapeutic effect that cannot be obtained with drug B, however much of drug B is given, then drug A has the higher therapeutic efficacy. Differences in therapeutic efficacy are of great clinical importance.

39. RELATION BETWEEN DRUG CONCENTRATION AND RESPONSE

40. RELATION BETWEEN DRUG CONCENTRATION AND RESPONSE
A agonist response in the absence of an antagonist
B low concentration antagonist
C larger concentration of antagonist
D and E spare receptors have been used up

43. quantal dose-response relationship
The response elicited with each dose of a drug is described in terms of the cumulative percentage subjects exhibiting a defined all-or-none effect and is plotted against the log dose of the drug
(prevention of convulsions, arrhythmia or death,relief of headache)

44. dose-response curves
% of population tested

46. QUANTAL DOSE-EFFECT PLOTS

47. ED50: median effective dose
The dose of a drug that produces a specified, desired effect in 50% of the animal population tested

48. Quantal dose-response relationships
Quantal dose-response relationships. The dose-response curves for a therapeutic effect (sleep) and a toxic effect (death) of a drug are compared. The ratio of the LD50 to the ED50 is the therapeutic index. The ratio of the LD1 to the ED99 is the certain safety factor. ED = effective dose; and
LD = lethal dose.

49. Subtherapeutic levels
Toxic levels
Drug plasma concen-tration
Therapeutic levels
Subtherapeutic levels

50. Therapeutic index (TI)
TI = TD 50
ED50
The ratio of the dose producing a specified toxic effect in 50% of the test population (TD50) to the dose producing a specified desired effect in 50% of the test population (ED50)

52. median toxic dose (TD50)
The dose of drug which produces a specified toxic effect in 50% of the animal population tested

53. therapeutic index (TI)
Also may be defined as:
LD50
ED50
Where LD50 is the median lethal dose – the dose of the drug that is lethal to 50% of the animal population tested

54. RELATION BETWEEN DRUG CONCENTRATION AND RESPONSE
E = Emax X C
C + EC50
E is the effect observed at concentration C,
Emax is the maximal response that can be produced by the drug
EC50 is the concentration of the drug that produces 50% of maximal effect

55. B = Bmax X C C + KD Bmax total concentration of receptor sites
KD the equilibrium dissociation constant, conc of free drug at which half-maximal binding is observed

56. IMATINIB INTERACTION WITH THE BCR-Abl kinase